Perspective Therapeutics, Inc. (CATX)
Largest Insider Buys in Sector
CATX Stock Price History Chart
CATX Stock Performance
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
Insider Activity of Perspective Therapeutics, Inc.
Over the last 12 months, insiders at Perspective Therapeutics, Inc. have bought $58.43M and sold $0 worth of Perspective Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Perspective Therapeutics, Inc. have bought $58.43M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lantheus Alpha Therapy, LLC (10 percent owner) — $57.41M. Williamson Robert F III (director) — $333,390. Spoor Johan M. (CEO) — $248,030.
The last purchase of 8,000 shares for transaction amount of $30,132 was made by Spoor Johan M. (CEO) on 2024‑12‑04.
List of Insider Buy and Sell Transactions, Perspective Therapeutics, Inc.
| 2024-12-04 | CEO | 8,000 0.0119% | $3.77 | $30,132 | -7.68% | |||
| 2024-12-04 | director | 25,975 0.0396% | $3.85 | $100,004 | -7.68% | |||
| 2024-11-25 | director | 6,266 0.0078% | $3.64 | $22,814 | -5.69% | |||
| 2024-11-25 | CEO | 26,500 0.0342% | $3.79 | $100,468 | -5.69% | |||
| 2024-11-25 | Chief Financial Officer | 12,829 0.0167% | $3.82 | $48,974 | -5.69% | |||
| 2024-06-17 | Chief Financial Officer | 1,800 0.006% | $9.81 | $17,667 | +16.92% | |||
| 2024-06-14 | director | 4,587 0.017% | $10.90 | $49,990 | +12.99% | |||
| 2024-06-13 | CEO | 100,000 0.0399% | $1.17 | $117,430 | +3.92% | |||
| 2024-06-03 | director | 34,246 0.017% | $1.46 | $49,992 | -11.53% | |||
| 2024-05-31 | director | 55,000 0.0258% | $1.38 | $75,900 | -11.96% | |||
| 2024-05-31 | Chief Financial Officer | 25,006 0.0119% | $1.40 | $35,007 | -11.96% | |||
| 2024-05-29 | director | 30,031 0.0136% | $1.33 | $40,014 | -9.93% | |||
| 2024-03-06 | 10 percent owner | 60.43M 19.5267% | $0.95 | $57.41M | +23.53% | |||
| 2024-01-30 | director | 127,206 0.0309% | $0.71 | $90,710 | +63.38% | |||
| 2024-01-29 | director | 25,266 0.0055% | $0.64 | $16,170 | +82.44% | |||
| 2024-01-26 | director | 110,613 0.0212% | $0.56 | $62,304 | +95.92% | |||
| 2024-01-25 | director | 22,134 0.0037% | $0.49 | $10,846 | +137.94% | |||
| 2024-01-24 | Chief Medical Officer | 280,000 0.0476% | $0.50 | $139,888 | +150.00% | |||
| 2024-01-24 | director | 29,862 0.005% | $0.49 | $14,632 | +150.00% |